Page 76 - Read Online

Page 72 Shi et al. Neuroimmunol Neuroinflammation 2020;7:68-72 I http://dx.doi.org/10.20517/2347-8659.2019.16

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. May ML, Dent S. Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a
patient with breast cancer: a case report and literature review. Curr Oncol 2018;25:e585-91.
2. Mitoma H, Adhikari K, Aeschlimann D, Chattopadhyay P, Hadjivassiliou M, et al. Consensus paper: neuroimmune mechanisms of
cerebellar ataxias. Cerebellum 2016;15:213-32.
3. Shams’ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, et al. Paraneoplastic cerebellar degeneration associated with
antineuronal antibodies: analysis of 50 patients. Brain 2003;126:1409-18.
4. Aliprandi A, Terruzzi A, Rigamonti A, Bazzigaluppi E, Tremolizzo L, et al. Paraneoplastic cerebellar degeneration with anti-CV2/
CRMP5 antibodies and prostate adenocarcinoma. Neurol Sci 2015;36:1501-3.
5. Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the
Lambert-Eaton myasthenic syndrome. Brain 1997;120:1279-300.
6. Sabater L, Saiz A, Dalmau J, Graus F. Pitfalls in the detection of CV2 (CRMP5) antibodies. J Neuroimmunol 2016;290:80-3.
7. Levy SE, Boone BE. Next-generation sequencing strategies. Cold Spring Harb Perspect Med 2019;9.
8. Bhardwaj S, Khasani S, Benasher D, Stein EG, Meghal T, et al. Paraneoplastic cerebellar degeneration in nasopharyngeal carcinoma:
a unique association. Cerebellum 2019;18:1126-9.
9. Abdulaziz ATA, Yu XQ, Zhang L, Jiang XY, Zhou D, et al. Paraneoplastic cerebellar degeneration associated with cerebellar
hypermetabolism: case report. Medicine (Baltimore) 2018;97:e10717.
10. Antoine JC. Peripheral neuropathies associated with antibodies directed to intracellular neural antigens. Rev Neurol (Paris)
2014;170:570-6.
11. Antoine JC, Camdessanche JP. Paraneoplastic neuropathies. Curr Opin Neurol 2017;30:513-20.
12. Badri KR, Gao L, Hyjek E, Schuger N, Schuger L, et al. Exonic mutations of TSC2/TSC1 are common but not seen in all sporadic
pulmonary lymphangioleiomyomatosis. Am J Respir Crit Care Med 2013;187:663-5.
13. Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, et al. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in
younger AML patients and leads to induction failure: a COG and SWOG report. Blood 2014;124:2400-7.
14. Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, et al. Down syndrome acute lymphoblastic leukemia, a highly
heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM
Study Group. Blood 2010;115:1006-17.
15. Bunda S, Heir P, Metcalf J, Li ASC, Agnihotri S, et al. CIC protein instability contributes to tumorigenesis in glioblastoma. Nat
Commun 2019;10:661.
16. Saloustros E, Zaganas I, Mavridis M, Vamvakas L, Plaitakis A, et al. Anti-CV2 associated cerebellar degeneration after complete
response to chemoradiation of head and neck carcinoma. J Neurooncol 2010;97:291-4.